http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
FDA approves Merck's subcutaneous KEYTRUDA QLEX across 38 cancer indications
-
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
-
Merck receives positive EU opinion for RSV prevention drug ENFLONSIA
-
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
-
Merck receives positive EU opinions for KEYTRUDA subcutaneous form and head cancer use
-
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
-
Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
-
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treate
-
Merck reports positive trial results for pneumonia vaccine in children
-
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
-
Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
-
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
-
Merck's oral cholesterol drug meets key goals in phase 3 trial
-
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
-
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
-
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
-
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
-
Daiichi Sankyo and Merck begin phase 3 breast cancer trial
-
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
-
Merck to present cardiovascular disease research at ESC Congress
-
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
-
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
-
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
-
KEYTRUDA plus Padcev improves survival for bladder cancer patients
-
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasiv
-
MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration
-
Merck Announces Fourth-Quarter 2025 Dividend
-
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
-
Merck launches phase 3 trials for monthly HIV prevention pill
-
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
-
FDA approves Merck's BRAVECTO QUANTUM for year-long flea and tick protection
-
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
-
FDA accepts Merck's application for HIV two-drug regimen
-
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
-
Merck to acquire Verona Pharma for $10 billion to add COPD treatment
-
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
-
Merck to present HIV research data at IAS 2025 conference
-
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
-
Merck (MRK) Granted FDA Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial
-
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
-
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
-
Merck (MRK) Reports ACIP Recommended Use of ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Younger than 8 Months
-
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During
-
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
-
Merck (MRK) Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint
-
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
-
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
-
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
-
Merck (MRK) Announces FDA Approval of KEYTRUDA for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment
-
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiother
